Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Transitional Cell Carcinoma
85%
Neoplasm
82%
Prostate Cancer
69%
Recurrent Disease
44%
Nephroureterectomy
41%
Prostatectomy
36%
Kidney Metastasis
33%
Malignant Neoplasm
31%
Castration Resistant Prostate Cancer
29%
Bladder Cancer
28%
Prostate Specific Antigen
27%
Non Muscle Invasive Bladder Cancer
25%
Magnetic Resonance Imaging
24%
Overall Survival
23%
Survival Rate
22%
Adrenalectomy
21%
Multivariate Analysis
21%
Sunitinib
19%
Disease
19%
Progression Free Survival
18%
Tumor Recurrence
18%
Metastatic Carcinoma
18%
Cystectomy
17%
Computer Assisted Tomography
17%
Subgroup Analysis
16%
Nivolumab
16%
Bacilli
16%
Biological Marker
16%
Cisplatin
15%
Cancer Specific Survival
14%
Biochemical Recurrence
14%
Recurrence Free Survival
14%
Brachytherapy
14%
Hazard Ratio
14%
Cancer Cell
14%
Biopsy
13%
Prognostic Factor
12%
Bladder Tumor
12%
Operation Duration
11%
Pembrolizumab
10%
Cabazitaxel
10%
Androgen Deprivation Therapy
10%
Angiomyolipoma
10%
Axitinib
10%
Targeted Therapy
10%
Kidney Function
10%
Gleason Score
10%
Lymphovascular Invasion
9%
Body Mass Index
9%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
88%
Neoplasm
59%
Transitional Cell Carcinoma
55%
Prostate Cancer
49%
Castration Resistant Prostate Cancer
48%
Kidney Metastasis
39%
Non Muscle Invasive Bladder Cancer
31%
Overall Survival
31%
Recurrent Disease
31%
Malignant Neoplasm
30%
Bladder Cancer
28%
Progression Free Survival
25%
Prostate Specific Antigen
22%
Axitinib
22%
Tumor Recurrence
20%
Survival Rate
20%
Androgen
20%
Chemotherapy
19%
Disease
18%
Sunitinib
17%
Biological Marker
16%
Docetaxel
16%
Cisplatin
15%
Cabazitaxel
14%
Sorafenib
14%
Avelumab
14%
Nivolumab
14%
Adverse Event
13%
Bacilli
12%
Bladder Tumor
11%
C Reactive Protein
11%
Retrospective Study
10%
Nuclear Factor
10%
Biochemical Recurrence
10%
Recurrence Free Survival
9%
Dehydroxymethylepoxyquinomicin
9%
Alternative Complement Pathway C3 C5 Convertase
9%
Mouse
8%
Interleukin 2
8%
Drug Resistance
7%
Cancer Specific Survival
7%
Vasculotropin
7%
Protein Tyrosine Kinase Inhibitor
7%
Kidney Cancer
6%
Dutasteride
6%
Cytokine
6%
Tumor Growth
6%
Pembrolizumab
6%
Angiotensin II
6%
Renin
5%
Keyphrases
Upper Tract Urothelial Carcinoma
28%
Advanced Renal Cell Carcinoma
27%
Renal Cell Carcinoma
21%
Metastatic Renal Cell Carcinoma (mRCC)
20%
Non-muscle Invasive Bladder Cancer (NMIBC)
16%
Clinical Outcomes
15%
Japan
14%
Castration-resistant Prostate Cancer
14%
Japanese Patients
14%
Nephroureterectomy
14%
Radical Prostatectomy
13%
Sunitinib
11%
Prostate Cancer Patients
11%
Avelumab
11%
Overall Survival
11%
Axitinib
11%
Cancer-specific Survival
10%
Tumor
10%
Cancer Patients
9%
Hazard Ratio
8%
Confidence Interval
8%
Prostate Cancer
8%
Bladder Cancer
8%
Sorafenib
8%
Vasohibin-1
8%
Biochemical Recurrence
7%
Programmed Death-ligand 1 (PD-L1)
7%
Progression-free Survival
7%
Nivolumab
7%
Prostate-specific Antigen
7%
Androgen Deprivation Therapy
6%
Muscle-invasive Bladder Cancer
6%
Renal Impairment
6%
Pembrolizumab
6%
International Metastatic Renal Cell Carcinoma Database Consortium
6%
Targeted Therapy
6%
Survival Rate
6%
Bacillus Calmette
6%
Subgroup Analysis
5%
Prognostic Value
5%
Multivariate Analysis
5%
Prognostic Significance
5%
Phase II Study
5%
Docetaxel
5%
Neoadjuvant Chemotherapy
5%
Radical Cystectomy
5%
Tumor Recurrence
5%
Recurrence-free Survival
5%
Localized Prostate Cancer
5%
Objective Response Rate
5%